Boehringer Ingelheim’s Biopharmaceutical Production Facility in Vienna, Austria
Germany-based pharmaceutical company Boehringer Ingelheim is constructing a new large-scale cell culture (LSCC) facility at its site in Vienna, Austria.
Boehringer Ingelheim
Contract Development and Manufacturing Services for Biopharmaceuticals
Binger Strasse 173,
55216 Ingelheim am Rhein,
Other,
Germany
The Boehringer Ingelheim Group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed for 125 years to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
Contract development and manufacture of biopharmaceuticals
Today, Boehringer Ingelheim is one of the world’s leading companies for contract development and manufacture of biopharmaceuticals. All types of services from mammalian cell line or microbial strain development to final drug production can be delivered within a one-stop-shop concept. Boehringer Ingelheim delivers services for pre-clinical development up to global market supply with a strong commitment to its customers at its manufacturing facilities for mammalian cell culture and microbial fermentation.
Boehringer Ingelheim has brought 18 molecules to market and has many years of experience in multiple molecule classes such as monoclonal antibodies, recombinant proteins, interferons, enzymes, fusion molecules and plasmid DNA. Furthermore, high-titer platform technologies for new antibody mimetic formats such as scaffold proteins and antibody fragments are available for the manufacture of customer products.
Contract manufacturing of mammalian cell culture products and biopharmaceuticals
Boehringer Ingelheim offers the entire production technology chain at its biopharmaceutical manufacturing facilities in Vienna (Austria), Fremont (US) and Biberach (Germany). It has the world’s largest capacities for contract development and manufacturing of mammalian cell culture products and is one of the leading manufacturers of biopharmaceuticals.
Boehringer Ingelheim
Boehringer Ingelheim’s experience: process development (including proprietary high-expression systems in CHO, E.coli and yeasts) and manufacturing of biopharmaceuticals such as therapeutic proteins, monoclonal antibodies, antibody fragments, protein scaffolds, and plasmid DNA for clinical trials and global market supply.
Boehringer Ingelheim’s services in biopharmaceuticals manufacturing include:
Mammalian cell culture
Features of Boehringer Ingelheim’s mammalian cell culture services:
- Clinical material capacities: 80l to 2,000l
- Production capacities: 6 x 2,000l to 2 x 12,000l and 12 x 15,000l
- Fed-batch operations
Microorganism fermentation
Boehringer Ingelheim’s microorganism fermentation services include:
- Clinical material capacities: 30l to 6,000l
- Production capacities: 1 x 300l to 2 x 6,000l
- Batch or fed-batch fermentation
Downstream processing services
Boehringer Ingelheim’s biopharmaceuticals manufacturing services include downstream processing services:
- Multi-product purification suites
- Explosion-proof unit and preparative HPLC
- Viral inactivation procedures
Pharmaceutical manufacturing services
Boehringer Ingelheim’s expertise extends to pharmaceutical manufacturing:
- Up to 150,000 vials per batch aseptic filling
- Up to 100,000 syringes per batch aseptic filling
- Up to 150,000 cartridges per batch aseptic filling
Opportunities for Boehringer Ingelheim’s partners
Boehringer Ingelheim’s wide-ranging capabilities and expertise offer many advantages for its partners, including:
- One-stop-shop from DNA to final dosage form
- Project start without initial investment
- Supply of biopharmaceuticals up to large quantities
- Worldwide-licensed multi-product facilities on safety level 1
Boehringer Ingelheim’s New Tablet Production Facility, Ingelheim
Germany-based pharmaceutical company, Boehringer Ingelheim, is constructing a new tablet production facility in Ingelheim, Germany, with an estimated investment of more than €85m ($97.2m).
Boehringer Ingelheim’s Integrated Asian Veterinary R&D Centre, Shanghai
Germany-based pharmaceutical company Boehringer Ingelheim’s veterinary research and development (R&D) centre is located within its research and development (R&D) site in Shanghai, China.
Boehringer Ingelheim Biologicals Development Centre (BDC), Biberach, Germany
Boehringer Ingelheim is developing a new biologicals development centre (BDC) within its Biberach plant site in Germany.
Lonza Houston’s Biotech Facility, Pearland, Texas
In April 2018, viral and cell therapy manufacturer Lonza Houston completed constructing a new biotech facility for immunotherapy development and manufacturing in Pearland, Texas, US.
Samsung BioLogics’ Third Manufacturing Facility, Songdo
Samsung BioLogics opened its third biologics manufacturing plant in Songdo, South Korea, in October 2018. The plant made Samsung Group one of the world’s largest biologics contract manufacturing operators (CMO) in the world.
Takeda Pharmaceutical’s High-Containment Production Facility, Grange Castle, Dublin
Japan-based pharmaceutical company Takeda has initiated construction of a new high-containment production facility at its existing site in Grange Castle Business Park in Dublin, Ireland.
Boehringer Ingelheim Research Institute of Molecular Pathology (IMP)
The construction of a new research premises for the Research Institute of Molecular Pathology (IMP) began in March 2015 at the Vienna Biocenter in the third district of Vienna, Austria.
Boehringer Ingelheim’s US Headquarters
Germany-based privately held pharmaceutical company Boehringer Ingelheim is involved in drug discovery, development and manufacturing.
Boehringer Ingelheim Wins Frost & Sullivan Award for Biopharmaceutical Contract Manufacturing
Boehringer Ingelheim has received the '2011 European Bio Pharmaceutical Contract Manufacturing Competitive Strategy Leadership Award' from Frost & Sullivan. The analysts recognised Boehringer Ingelheim Biopharmaceuticals as a global contract manufacturer that delivers excellence an
Boehringer Ingelheim Licenses ProBioGen’s Novel GlymaxX® Technology
Boehringer Ingelheim and ProBioGen have announced that they have signed a non-exclusive licensing agreement regarding ProBioGen's GlymaxX® technology. Boehringer Ingelheim's Contract Manufacturing Business will apply the technology to enhance ADCC (antibody-dependent cell-mediated cytotoxici
Boehringer Ingelheim Extends ‘One Stop Shop’ Service with New Fill and Finish Capabilities
To round off its full-service capabilities for clients, Boehringer Ingelheim is expanding its capacities and capabilities in fill and finish for biopharmaceuticals at its state-of-the-art facility in Biberach, Germany, with a new filling line. The new line is available as of today for contract f
Boehringer Ingelheim Extends its Manufacturing Agreement for Betaferon® with Bayer HealthCare
Boehringer Ingelheim has announced the US-registration for manufacturing of Bayer HealthCare's Betaferon® against multiple sclerosis. Recently Bayer HealthCare has extended the commercial production agreement for Betaferon with Boehringer Ingelheim, which received the FDA approval for Betafe
Pfenex and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement for the Use of Pfenex Expression Technology™
Pfenex, an industry leader in protein expression through the Pfenex Expression Technology™ platform, and Boehringer Ingelheim International, a leading pharmaceutical company and global leader in biopharmaceutical contract development and manufacture, announced today that th
Boehringer Ingelheim and VTU Technology Collaboration Benefits Customers with Broader Services
Boehringer Ingelheim, a global leader in biopharmaceutical contract development and manufacture, and VTU Technology, a leading supplier of exclusive technologies and comprehensive services for the development of high-performance Pichia pastoris protein expression strains, announced today that the
Boehringer Ingelheim Pharma GmbH & Co. KG
Binger Strasse 173
55216 Ingelheim am Rhein
Other
Germany
